Alnylam® and Amyloidosis Research
Genetic Testing and Counseling Program*† for Acute Hepatic Porphyria (AHP) Offered at No Charge‡
Genetic Testing & Counseling | Alnylam Act® | Patient Guide
Genetic Counseling and Testing Programs*† for Hereditary ATTR (hATTR) Amyloidosis Offered at No Charge‡
Alnylam erhält positive CHMP-Stellungnahme zu Vutrisiran für die Behandlung der hereditären Transthyretin-vermittelten Amyloidose (hATTR) bei erwachsenen Patienten mit Polyneuropathie im Stadium 1 oder Stadium 2 | Business Wire
Alnylam Pharmaceuticals on Twitter: "Symptoms of acute hepatic #porphyrias are similar to those of other diseases, resulting in frequent misdiagnosis. Genetic testing through Alnylam Act may help: https://t.co/q9990gYwya https://t.co/oLYz6BU69U" / Twitter
Invitae | Alnylam Act Hereditary ATTR Amyloidosis
ALNYLAM ACT Trademark of Alnylam Pharmaceuticals, Inc. - Registration Number 5498799 - Serial Number 87340411 :: Justia Trademarks
Additional PH1 Resources | Behind the Stone™
Testes genéticos
IRA Effect: Alnylam Acting 'Rationally' In Halting Second Orphan Indication For Amvuttra – Analysts :: Pink Sheet
Invitae | Alnylam Act Hereditary ATTR Amyloidosis
Genetic Testing & Counseling | Alnylam Act® | Patient Guide
Acute Hepatic Porphyria Resources | Porphyria.ca
Genetic Testing & Counseling | Alnylam Act® | Guide for HCPs
Alnylam® Information for Medical Professionals
ALNYLAM PHARMACEUTICALS, INC.
Alnylam Pharmaceuticals, Inc.: Alnylam und Regeneron melden positive klinische Zwischenergebnisse der Phase 1 zu ALN-APP, einem RNAi-Prüftherapeutikum für Alzheimer-Krankheit und zerebrale Amyloidangiopathie
Downloadable Resources | Pinpoint AHP®
The Alnylam Act Program for AHP Patients | Alnylym Pharmaceuticals
Alnylam® and Amyloidosis Research
Invitae - TRF930_Alnylam_ActAHP_reqform - Page 1
Acute Hepatic Porphyria Resources | Porphyria.ca
Amvuttra, an Onpattro follow-on drug, gets approved for RNA therapy | Fierce Pharma
Invitae | Alnylam Act Hereditary ATTR Amyloidosis
